Post-Ranbaxy Laboratories, Sun Pharma Looks to Divest Ireland Plant to Cut Costs
(Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.
The world's fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.
"Decisions are being made to either close or divest some of our manufacturing facilities," a Sun Pharma spokesman said in an emailed statement.
Help employers find you! Check out all the jobs and post your resume.
The world's fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.
"Decisions are being made to either close or divest some of our manufacturing facilities," a Sun Pharma spokesman said in an emailed statement.
Help employers find you! Check out all the jobs and post your resume.